tiprankstipranks
Trending News
More News >
Elicio Therapeutics (ELTX)
NASDAQ:ELTX
Advertisement

Elicio Therapeutics (ELTX) AI Stock Analysis

Compare
211 Followers

Top Page

ELTX

Elicio Therapeutics

(NASDAQ:ELTX)

Select Model
Select Model
Select Model
Underperform 30 (OpenAI - 4o)
Rating:30Underperform
Price Target:
Elicio Therapeutics faces significant financial challenges, with negative revenue growth and poor margins being the primary concerns. Technical analysis indicates bearish momentum, while the valuation aspect shows limited appeal. However, recent positive corporate events, such as leadership changes and clinical advancements, provide some optimism for future potential, albeit with high risk.
Positive Factors
Strategic Leadership Change
The appointment of a new CFO with extensive experience in corporate finance and strategy is expected to strengthen Elicio's strategic alignment and financial planning, potentially enhancing the company's ability to advance its immunotherapy platform and achieve clinical milestones.
Clinical Advancements
Advancements in clinical programs, particularly with lead product candidates like ELI-002, are crucial for long-term growth and success in the biotech industry, potentially leading to new revenue streams and partnerships.
Innovative Immunotherapy Platform
Elicio's proprietary Amphiphile platform enhances the potency and durability of immune responses, providing a competitive advantage in the development of cancer vaccines and immune-modulating therapies, which is essential for long-term success in the biotech sector.
Negative Factors
Negative Revenue Growth
Negative revenue growth indicates difficulties in generating sales, which can hinder the company's ability to invest in R&D and expand its market presence, posing a risk to long-term sustainability.
Poor Margins
Consistently poor margins reflect inefficiencies and financial challenges, which can limit the company's ability to reinvest in its operations and achieve profitability, affecting long-term viability.
Reliance on External Financing
Dependence on external financing due to negative cash flows can lead to financial instability and increased risk, as the company may face challenges in securing necessary funding to sustain operations and growth.

Elicio Therapeutics (ELTX) vs. SPDR S&P 500 ETF (SPY)

Elicio Therapeutics Business Overview & Revenue Model

Company DescriptionElicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.
How the Company Makes MoneyElicio Therapeutics makes money primarily through the development and commercialization of its proprietary immunotherapy products. The company generates revenue by partnering with pharmaceutical companies for the co-development and licensing of its technologies. These partnerships often involve upfront payments, milestone payments based on the achievement of specific development goals, and royalties on future sales. Additionally, Elicio may receive funding from grants and research collaborations with academic institutions and government agencies, which contribute to its earnings.

Elicio Therapeutics Financial Statement Overview

Summary
Elicio Therapeutics is in a challenging financial position with negative revenue growth, poor margins, and reliance on external financing. The negative equity and cash flow issues highlight significant financial instability.
Income Statement
10
Very Negative
Elicio Therapeutics has faced declining revenues over the years, with no revenue reported for the latest periods. This has resulted in negative margins across the board, including gross profit, EBIT, and net income margins.
Balance Sheet
15
Very Negative
The company has negative stockholders' equity, indicating a high level of leverage and financial instability. The debt-to-equity ratio cannot be calculated due to negative equity, which is a significant concern for financial health.
Cash Flow
20
Very Negative
Elicio Therapeutics has consistently negative operating and free cash flows, indicating challenges in generating cash from its operations. The financing cash flows are positive, suggesting reliance on external funding.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.17M0.000.000.0028.31M2.88M
Gross Profit-266.00K-1.18M-1.17M-1.06M27.08M1.06M
EBITDA-52.72M-50.27M-32.97M-23.55M-51.92M-15.53M
Net Income-54.61M-51.90M-35.20M-28.21M-26.40M-15.71M
Balance Sheet
Total Assets29.53M28.18M27.15M22.66M14.81M19.66M
Cash, Cash Equivalents and Short-Term Investments22.09M17.62M12.89M6.16M9.28M14.97M
Total Debt14.90M26.04M6.92M7.48M11.80M85.04M
Total Liabilities27.69M39.49M15.77M124.81M89.35M3.31M
Stockholders Equity1.83M-11.31M11.37M8.91M-74.54M-90.45M
Cash Flow
Free Cash Flow-35.13M-37.16M-32.76M-22.83M-24.46M-16.90M
Operating Cash Flow-35.09M-37.07M-32.69M-22.18M-23.94M-16.70M
Investing Cash Flow-45.00K-84.00K-32.00K-654.00K-525.36K-199.92K
Financing Cash Flow53.24M42.32M38.61M21.20M19.39M25.06M

Elicio Therapeutics Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price11.09
Price Trends
50DMA
10.42
Positive
100DMA
8.78
Positive
200DMA
7.73
Positive
Market Momentum
MACD
0.24
Positive
RSI
51.74
Neutral
STOCH
41.73
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELTX, the sentiment is Neutral. The current price of 11.09 is above the 20-day moving average (MA) of 11.07, above the 50-day MA of 10.42, and above the 200-day MA of 7.73, indicating a neutral trend. The MACD of 0.24 indicates Positive momentum. The RSI at 51.74 is Neutral, neither overbought nor oversold. The STOCH value of 41.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ELTX.

Elicio Therapeutics Risk Analysis

Elicio Therapeutics disclosed 35 risk factors in its most recent earnings report. Elicio Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Elicio Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
43
Neutral
100.70M-0.8435.81%
41
Neutral
196.10M-1.6439.76%
39
Underperform
264.93M-0.2729.56%72.33%
36
Underperform
254.24M-1.6238.94%
33
Underperform
185.61M13.77
30
Underperform
$182.01M-9999.00%-4.60%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ELTX
Elicio Therapeutics
11.05
5.99
118.38%
BDTX
Black Diamond Therapeutics
3.26
-0.94
-22.38%
SRZN
Surrozen
11.75
1.55
15.20%
JBIO
Jade Biosciences
8.12
0.92
12.78%
TNYA
Tenaya Therapeutics
1.56
-0.38
-19.59%
VTYX
Ventyx Biosciences
2.75
0.36
15.06%

Elicio Therapeutics Corporate Events

Executive/Board ChangesBusiness Operations and Strategy
Elicio Therapeutics Appoints New Chief Strategy and Financial Officer
Positive
Mar 24, 2025

On March 21, 2025, Elicio Therapeutics appointed Preetam Shah, Ph.D., M.B.A., as Chief Strategy and Financial Officer, effective March 24, 2025. Dr. Shah’s extensive experience in corporate finance and strategy is expected to be a significant asset as Elicio advances its immunotherapy platform and prepares for key clinical milestones. His appointment comes at a crucial time for the company, which is focusing on the development of its lead product candidate, ELI-002, and other cancer vaccines. This strategic leadership change is anticipated to bolster Elicio’s efforts in aligning financial and corporate strategies with its goal of delivering cutting-edge cancer immunotherapeutics.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 22, 2025